Open house pharmaceutical rebate agreements for Alfacalcidol, ATC A11CC03
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Alfacalcidol, ATC A11CC03
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
Agreements can be automatically superseded by future competitive rebate contracts, reducing potential volume.
Strict submission requirements: paper must be 2 copies, hand-signed; electronic requires qualified signature; both must...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jan 2028
- Non-exclusive pharmaceutical rebate agreements (Rabattverträge) under §130a(8) SGB V
- Active substance: Alfacalcidol, ATC code A11CC03
Show full summary
Open house non-exclusive rebate agreement for the active ingredient Alfacalcidol (ATC A11CC03) by AOK Bayern. All interested pharmaceutical companies meeting eligibility criteria can join. No competitive selection; contract terms are fixed. Early contract start possible from 01.02.2026, with all contracts ending 31.01.2028. Final date for contract conclusion is 03.12.2027.
Risks
Agreements can be automatically superseded by future competitive rebate contracts, reducing potential volume.
Strict submission requirements: paper must be 2 copies, hand-signed; electronic requires qualified signature; both must...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible
Certifications
- Documents must be in German or accompanied by a certified German translation
Administrative
- Submit signed contract, signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed declaration of reliability
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house pharmaceutical rebate agreements for Alfacalcidol, ATC A11CC03
Non-exclusive rebate agreements for the active ingredient Alfacalcidol. Open to all qualified pharmaceutical companies. Contract duration 24 months. Submission monthly by the 3rd for next month start. No award criteria or competition.
Location
Duration
Category
Award Criteria
Deadline
Award details
No award criteria (open house model)
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Alfacalcidol, ATC A11CC03
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 14 Dec 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 829127-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
Agreements can be automatically superseded by future competitive rebate contracts, reducing potential volume.
Strict submission requirements: paper must be 2 copies, hand-signed; electronic requires qualified signature; both must...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications